Benedict Yan

Benedict Yan

Auto-generated profile, based on publicly available information

Benedict Yan

Department of Laboratory Medicine, National University Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ZLZhentang Lao
Zhentang Lao
LDLing-Wen Ding
Ling-Wen Ding
QSQiaoyang Sun
Qiaoyang Sun
LJLi Jia
Li Jia
BYBenedict Yan
Benedict Yan
NGNicholas Grigoropoulos
Nicholas Grigoropoulos
Purpose: DNA methylation alterations are widespread in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), some of which appear to have evolved independently of somatic mutations in epigenetic regulators. Although the presence of somatic mutations in peripheral blood can predict the risk of development of AML and MDS, its accuracy remains unsatisfactory.Experimental Design: We performed global DNA methylation profiling in a case control study nested within the Singapore Chinese Health Study to evaluate whether DNA methylation alterations were associated with AML/MDS development. Targeted deep sequencing and methylated DNA immunoprecipitation sequencing (MeDIP-seq) were performed on peripheral blood collected a median of 9.9 years before diagnosis of AML or MDS, together with age-matched still-healthy individuals as controls.Results: Sixty-six individuals who developed AML or MDS displayed significant DNA methylation changes in the peripheral blood compared with 167 age- and gender-matched controls who did not develop AML/MDS during the follow-up period. Alterations in methylation in the differentially methylation regions were associated with increased odds of developing AML/MDS.Conclusions: The epigenetic changes may be acquired independently and before somatic mutations that are relevant for AML/MDS development. The association between methylation changes and the risk of pre-AML/MDS in these individuals was considerably stronger than somatic mutations, suggesting that methylation changes could be used as biomarkers for pre-AML/MDS screening.

15 May 2024
Verified
Other
Open access
ZLZhentang Lao
Zhentang Lao
LDLing-Wen Ding
Ling-Wen Ding
QSQiaoyang Sun
Qiaoyang Sun
LJLi Jia
Li Jia
BYBenedict Yan
Benedict Yan
NGNicholas Grigoropoulos
Nicholas Grigoropoulos
Purpose:DNA methylation alterations are widespread in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), some of which appear to have evolved independently of somatic mutations in epigenetic regulators. Although the presence of somatic mutations in peripheral blood can predict the risk of development of AML and MDS, its accuracy remains unsatisfactory.Experimental Design:We performed global DNA methylation profiling in a case control study nested within the Singapore Chinese Health Study to evaluate whether DNA methylation alterations were associated with AML/MDS development. Targeted deep sequencing and methylated DNA immunoprecipitation sequencing (MeDIP-seq) were performed on peripheral blood collected a median of 9.9 years before diagnosis of AML or MDS, together with age-matched still-healthy individuals as controls.Results:Sixty-six individuals who developed AML or MDS displayed significant DNA methylation changes in the peripheral blood compared with 167 age- and gender-matched controls who did not develop AML/MDS during the follow-up period. Alterations in methylation in the differentially methylation regions were associated with increased odds of developing AML/MDS.Conclusions:The epigenetic changes may be acquired independently and before somatic mutations that are relevant for AML/MDS development. The association between methylation changes and the risk of pre-AML/MDS in these individuals was considerably stronger than somatic mutations, suggesting that methylation changes could be used as biomarkers for pre-AML/MDS screening.


15 May 2024
Verified
Other
Open access
ZLZhentang Lao
Zhentang Lao
LDLing-Wen Ding
Ling-Wen Ding
QSQiaoyang Sun
Qiaoyang Sun
LJLi Jia
Li Jia
BYBenedict Yan
Benedict Yan
NGNicholas Grigoropoulos
Nicholas Grigoropoulos
Supplementary Table 5 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy

15 May 2024
Verified
Other
Open access
ZLZhentang Lao
Zhentang Lao
LDLing-Wen Ding
Ling-Wen Ding
QSQiaoyang Sun
Qiaoyang Sun
LJLi Jia
Li Jia
BYBenedict Yan
Benedict Yan
NGNicholas Grigoropoulos
Nicholas Grigoropoulos
Supplementary Table 5 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy